Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
0Activity
0 of .
Results for:
No results containing your search query
P. 1
pipeline_2010_0127

pipeline_2010_0127

Ratings: (0)|Views: 3|Likes:
Published by jennabush

More info:

Published by: jennabush on Jun 24, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

04/28/2013

pdf

text

original

PfizerPipeline
PfizerPipeline
as of January 27, 2010
as of January 27, 2010

As some programs are still confidential, some
candidates may not be identified in this list. In
these materials, Pfizer discloses Mechanism of
Action (MOA) information for candidates from
Phase 3 through regulatory approval. With a view
to expanding the transparency of our pipeline,
Pfizer is including new indications or
enhancements, which target unmet medical need
or represent significant commercial opportunities.
The information contained on these pages is
correct as of January 27, 2010.

As some programs are still confidential, some
candidates may not be identified in this list. In
these materials, Pfizer discloses Mechanism of
Action (MOA) information for candidates from
Phase 3 through regulatory approval. With a view
to expanding the transparency of our pipeline,
Pfizer is including new indications or
enhancements, which target unmet medical need
or represent significant commercial opportunities.
The information contained on these pages is
correct as of January 27, 2010.

Visit Pfizer.com/pipeline

Visit Pfizer.com/pipeline, Pfizer’s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

The information provided on this page is for general information only and is subject to the Terms of Use. It is not intended to
provide medical advice or guidance, and should not be used for that purpose. Medical use of any product should be strictly in
accordance with the approved prescribing information. Copyright © 2010 Pfizer Inc.
All rights reserved.

Pfizer Pipeline – as of January 27, 2010
The information provided on this page is for general information only and is subject to the Terms of
Table of Contents
Pfizer Pipeline Snapshot................................................................................................... 3
Pfizer Pipeline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Phase 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Phase 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Phase 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Recent Approval...... ...................................................................................................... 10 Assets Transferred to ViiV Healthcare...... ..................................................................... 10 Projects Discontinued from Development since March 31, 2009. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Phases of Development. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

The Phases of Clinical Development............................................................................. 11 Registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... 12 Recent Approvals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Phase 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .... 12

Product Pipeline Therapeutic Areas and Conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Allergy & Respiratory..................................................................................................... 13 Cardiovascular, Metabolic and Endocrine Diseases (CVMED). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Gastrointestinal.............................................................................................................. 15 Genitourinary................................................................................................................. 15 Infectious Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Inflammation.................................................................................................................. 16 Neuroscience. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Oncology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Ophthalmology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Pain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....... 21

Use. It is not intended to provide medical advice or guidance, and should not be used for that
purpose. Medical use of any product should be strictly in accordance with the approved prescribing
information. Copyright © 2010 Pfizer Inc.
All rights reserved.

Page2 of22
Pfizer Pipeline – as of January 27, 2010

The information provided on this page is for general information only and is subject to the Terms of
Use. It is not intended to provide medical advice or guidance, and should not be used for that
purpose. Medical use of any product should be strictly in accordance with the approved prescribing
information. Copyright © 2010 Pfizer Inc.
All rights reserved.

Page3 of22
Pfizer Pipeline Snapshot January 27, 2010
Phase 2
Phase 2
Phase 3
Phase 3
In Reg.
In Reg.
49
49
44
44
34
34
6
6
Phase 1
Phase 1
Total
Total
133
133
Discovery
Discovery
Projects
Projects
63 programs advanced
63 programs advanced
63 programs advanced
Pipeline represents progress of R&D programs since 3/31/09
Included are 100 NMEs plus 33 additional indications

13 Projects Discontinued
since last update
4 Projects Transferred to
ViiV Healthcare
1 Project Out-Licensed

(dalbavancin)
Recent Approvals
Recent Approvals
Prevenar
Prevenar13 Infant
13 Infant
(MAA)
(MAA)
Geodon
Geodon(Bipolar
(Bipolar
Relapse Prevention)
Relapse Prevention)
Pfizer Pipeline Snapshot March 31, 2009
Phase 2
Phase 2
Phase 3
Phase 3
In Reg.
In Reg.
40
40
33
33
25
25
2
2
Phase 1
Phase 1
Total
Total
100
100
Discovery
Discovery
Projects
Projects
21 programs advanced
21
21programs advanced
programs advanced
26
26Projects Discontinued since last update
Projects Discontinued since last update
15
15Strategic decisions to stop work and
Strategic decisions to stop work and
reallocate resources
reallocate resources
11
11Candidate attrition
Candidate attrition
1 Indication attrited in Phase 2; candidate
1 Indication attrited in Phase 2; candidate
remains in Phase 1
remains in Phase 1
Recent Approval
Recent Approval
Fablyn (MAA)
Fablyn (MAA)
Pipeline represents progress of R&D programs since 9/30/08
Included are 76 NME plus 24 additional indications

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->